Market Cap (In KRW)
106.1 Billion
Revenue (In KRW)
76.03 Billion
Net Income (In KRW)
-9.32 Billion
Avg. Volume
326.39 Thousand
- Currency
- KRW
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1047.0-2220.0
- PE
- -
- EPS
- -
- Beta Value
- 1.514
- ISIN
- KR7183490002
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Ki-Young Sohn
- Employee Count
- -
- Website
- http://www.enzychem.com
- Ipo Date
- 2017-04-05
- Details
- Enzychem Lifesciences Corporation, a pharmaceutical company, focuses on the development of oral small molecule therapies for patients with unmet medical needs for oncology, metabolic diseases, and inflammatory diseases in South Korea. It is also developing potential therapies based on EC-18 technology platform to treat chemotherapy-induced neutropenia, chemoradiation therapy-induced oral mucositis, and acute radiation syndrome. The company was founded in 1999 and is headquartered in Seoul, South Korea.
More Stocks
-
OBIO
-
MDPR
-
DIANATEADiana Tea Company Limited
DIANATEA
-
ZDGGFZOO Digital Group plc
ZDGGF
-
GOKULAGROGokul Agro Resources Limited
GOKULAGRO
-
CZT
-
PXP10, Inc.
PX
-
SABTNLSRI ADHIKARI BROS
SABTNL